Compare PXED & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PXED | DRTS |
|---|---|---|
| Founded | 1976 | 2015 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medical/Dental Instruments |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.0B |
| IPO Year | 2025 | 2021 |
| Metric | PXED | DRTS |
|---|---|---|
| Price | $26.99 | $14.69 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | ★ $44.29 | $8.67 |
| AVG Volume (30 Days) | 131.8K | ★ 558.9K |
| Earning Date | 04-07-2026 | 05-18-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.69 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.85 | N/A |
| Revenue Next Year | $4.49 | $699.98 |
| P/E Ratio | $15.94 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.52 | $3.01 |
| 52 Week High | $38.19 | $14.40 |
| Indicator | PXED | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 37.41 | 66.19 |
| Support Level | $26.06 | $6.59 |
| Resistance Level | $31.13 | N/A |
| Average True Range (ATR) | 1.33 | 0.76 |
| MACD | -0.19 | 0.16 |
| Stochastic Oscillator | 14.49 | 97.88 |
Phoenix Education Partners Inc. is a mission-driven organization operating at the forefront of the rapidly evolving post-secondary education market. it is an online education provider and a pioneer in its field. The company benefits from the dynamic interplay between technological innovation, education, employment, and economic trends. It is focused on delivering personalized, career-relevant, and affordable education to its students through its flexible learning model, skills-aligned curriculum, and accessible tuition costs.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.